Does anyone have more information about this - CLL Support

CLL Support

23,337 members40,045 posts

Does anyone have more information about this

Tunde_s profile image
9 Replies

Culled from euro news.

Scientists say tests of a potentially groundbreaking new cancer therapy have had “extraordinary” results.

More than 90 percent of terminally ill Leukemia patients tested have reportedly gone into remission.

The therapy involves taking patients’ white blood cells, modifying them and putting them back.

However, the data has not yet been reviewed. Two patients are said to have died during testing after suffering an extreme immune response.

Lead scientist Professor Stanley Riddell labelled the early data “unprecendented”.

He told the annual meeting of the American Association for the Advancement of Science that all other treatments had failed in the patients tested and they had only initially been given only two to five months to live.

Written by
Tunde_s profile image
Tunde_s
To view profiles and participate in discussions please or .
Read more about...
9 Replies
AussieNeil profile image
AussieNeilPartnerAdministrator

Must be a slow news week in Europe as this 'news' is nearly 5 years old - assuming it is about Chimeric Antigen Receptor T- Cell therapy (CAR-T therapy) where you take T-Lymphocytes (one of the white blood cell types) and genetically modify them so they will search out and kill the cancerous leukaemia cells (and unfortunately healthy cells of the same type as the leukaemia cells too).

The Leukemia and Lymphoma Society has an excellent article on CAR-T therapy

lls.org/treatment/types-of-...

There's even a Wikipedia page on this - commenced in March 2005!

en.wikipedia.org/wiki/Chime...

And there have been multiple posts about CAR-T therapy over the years to this community because the really big breakthrough happened 4 and a half years ago, when several CLL patients with no remaining treatment options were given CAR-T therapy with very encouraging results.

The Euro News article probably picked up the 'news' as reported here...

healthunlocked.com/cllsuppo....

healthunlocked.com/cllsuppo....

Neil

Myrddin profile image
Myrddin in reply toAussieNeil

"The news bubbled out of the American Association for the Advancement of Science's annual meeting in Washington DC.

The lead scientist, Prof Stanley Riddell from the Fred Hutchinson Cancer Research Centre in Seattle, said all other treatments had failed in these patients and they had only two-to-five months to live"

Very current - It is based on T cell retraining - no mention of which blood cancer was being trialled but don't think these results referred to CLL.

AussieNeil profile image
AussieNeilPartnerAdministrator in reply toMyrddin

Thanks for the extra information, but it's still an extension of the original CAR-T research:

fredhutch.org/en/news/cente...

"Some of the patients in the trial, which began in 2013, were originally not expected to survive for more than a few months because their disease had previously relapsed or was resistant to other treatments, said Dr. Stanley Riddell, an immunotherapy researcher and oncologist Fred Hutch. Today, there is no sign of disease.

:

:

The trial is designed to test the safety of the latest iteration of an experimental immunotherapy in which a patient’s own T cells are reprogrammed to eliminate his or her cancer. The reprogramming involves genetically engineering the T cells with synthetic molecules called chimeric antigen receptors, or CARs, that enable them to target and destroy tumor cells bearing a particular target. Trial participants include patients with acute lymphoblastic leukemia, non-Hodgkin lymphoma and chronic lymphocytic leukemia. (My emphasis)

Still, it's good to see that active research is continuing into CAR-T therapy, because as Chris has pointed out, there remain significant barriers to making this technique widely useable.

Neil

Cllcanada profile image
CllcanadaTop Poster CURE Hero in reply toAussieNeil

Fred Hutch is working with Juno, Novartis with UPENN and Kite with Sloan Kettering

junotherapeutics.com/about-...

But Cellectis/Pfizer has an off the shelf T cell so they are currently out front as this rounds the quarter mile post... 🏇🏇🏇

cellectis.com/sites/default...

reuters.com/article/us-pfiz...

wmay13241 profile image
wmay13241 in reply toAussieNeil

AussieNeil is right - CAR-T clinical trials were started about 10 years ago. Unfortunately today CAR-T treatment is tailored to an individual's specific blood cancer and only available in clinical trials. Lots of CAR-T information is available (including clinical trials) at: lymphomation.org/programing...

MaudMarie profile image
MaudMarie

Cancer Research UK have written a cautionary note on their website about the media reporting on this - not yet peer reviewed and high proportion of adverse events.

Great idea though but needs to be a lot safer.

I saw a professor talking about this T cell immunology on a tv program. He said it would take 5 to 10 years' to fine tune this treatment.

Cllcanada profile image
CllcanadaTop Poster CURE Hero

Not to burst 'hope' bubbles...it is frankly not great in CLL, there are issues to be resolved, cost being one of them... might one day replace stem cell transplant... certainly won't be first or second line therapy...

They now have an 'off the shelf' T cell, so they don't need to harvest each patient's T cell, which will reduce costs... into the $500,000 range

In CLL there still remains the issue of cytokine storms... which can be fatal and the need for life long IVIG infusions...

This clearly will be used on childhood leukemias, particularly ALL, where it has been wonderful...

Still experimental...

Sad to know. If it sounds to good to be true, it is likely not true. Shame on the people whom feed on victim of disease.

The first time Cll has a cure and it is free. Call me then. Until then I likely do not have enough money. But, more importantly I have a happy life.

Not what you're looking for?

You may also like...

An Early Look at When CAR-T Therapy Fails Patients With CLL

Not exactly an optimistic report. Dr James Gerson, MD, - "Not a lot is known as to what happens in...
Jm954 profile image
Administrator

Leukaemia Care Webinar 8th April - a bit more information

Professor Dr Chris Fegan talked about CLL and COVID19 and answered previously submitted questions....
Jm954 profile image
Administrator

BTK inhibitor challenges by Dr. Nicole Lamanna

Nicole Lamanna, MD, continues her discussion on BTK inhibitor challenges....
lankisterguy profile image
Volunteer

Outcomes of COVID-19 in Patients with CLL: A Multicenter, International Experience

This is the full report from ASH Publications Blood Journam yesterday by Dr Mayo et al....
Jm954 profile image
Administrator

Resistance-Associated Mutations in CLL Patients Treated With Novel Agents

This is slightly complex but good overview of the acquired resistance mechanisms to novel agents....
Jm954 profile image
Administrator